What We Do
Transformative Therapies for Autoimmune Disease
Translating the biology of regulatory T cells into transformational medicines for patients.
The Abata Approach
A New Era: Treg Cell Therapy
Our targeted, autologous Treg cell therapies for progressive multiple sclerosis and other serious autoimmune diseases stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in affected tissues.
Who We Are
A team committed to groundbreaking science and patients
We are industry experts and scientific pioneers working together to bring an entirely new approach to the treatment of autoimmune disease.
We welcome Monday mornings
We’re pushing the frontiers of science together, and we take joy in our work. We value people and believe in limitless possibilities, the power of diversity and the importance of kindness.
Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis
ABA-101 aims to benefit a subset of progressive MS patients with no treatment options. ABA-101 is currently in IND-enabling studies and on track to enter the clinic in 2024.